⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of AngioSafe, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
AngioSafe, Inc.
↗San Jose, USA
AngioSafe is a medical technology company focused on developing innovative, catheter-based devices to improve the safety and efficacy of cardiovascular interventions, particularly for complex coronary and peripheral arterial diseases. The company's proprietary Atheroplasty™ technology platform is designed to simplify revascularization procedures for chronic total occlusions (CTOs) without requiring external power sources.
Since its founding in 2014, the company has transitioned from a research-focused entity to a commercial-stage organization. Its flagship product, the Santreva™-ATK endovascular revascularization catheter, has received both FDA 510(k) clearance and CE marking, enabling its commercial availability in the U.S. and Europe.
CLASSIFICATION
Company Type:MedTech
Therapeutic Areas:
Industry:Medical Devices
Sub-Industry:Interventional Cardiology
SIZE & FINANCIALS
Employees:1-50
Founded:2014
Ownership:private
Status:operating
FUNDING
Stage:Seed
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (Santreva-ATK)
Modalities:Catheter-based devices
Active Trials:0
Trial Phases:-
FDA Approvals:1
EMA Approvals:1
CORPORATE STRUCTURE
Key Partnerships:Gada Italia (Distribution partner in Italy)
COMPETITION
Position:Emerging
Competitors:SMT, Aortyx, Terumo Medical
LEADERSHIP
Key Executives:
Sarvajna Dwivedi - CEO, Co-Founder
Mallik Thatipelli - Co-Founder
Ram Reddy - Co-Founder
Scientific Founders:Mallik Thatipelli, Ram Reddy
LINKS
Website:angiosafe.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with AngioSafe, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.